Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2023 07:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
August 18, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
December 01, 2021 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
October 25, 2021 07:40 ET | Source: Sab Biotherapeutics, Inc.

SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D.,...
April 29, 2021 06:00 ET | Source: InspireMD Inc.

InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board

TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by...